Khondrion | News

Khondrion press releases

November 21, 2024

UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease

The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion...

November 14, 2024

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...

November 8, 2024

Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms

Khondrion, a clinical-stage biopharmaceutical company specializing in mitochondrial disease therapies,...

November 7, 2024

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...

October 29, 2024

Khondrion to Present Promising Advances in Mitochondrial Disease Therapy at Bio-Europe and Investival Showcase Events

NIJMEGEN, The Netherlands – October 29, 2024: Khondrion, a pioneering clinical-stage biopharmaceutical company focused on developing transformative...

October 9, 2024

Khondrion to present at Mitocon’s 14th Mitochondrial Disease Conference

NIJMEGEN, the Netherlands – 9 October, 2024: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...

our stories

October 31, 2015

Khondrion welcomes Hans Schikan

Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...

stay updated

Khondrion press releases

UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

Khondrion to Present Promising Advances in Mitochondrial Disease Therapy at Bio-Europe and Investival Showcase Events

Khondrion to present at Mitocon’s 14th Mitochondrial Disease Conference

our stories

Khondrion welcomes Hans Schikan

office

contact

legal